Physician profile
John Humphrey
NPI 1275575169
$1,704.38
in general payments reported to CMS, 2019-2025
17 companies · $40.68 in 2025
The $40.68 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,613 · 2021: $16.14 · 2022: $13.07 · 2024: $21.54 · 2025: $40.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $356.05 | 2019 | |
| Sunovion Pharmaceuticals INC. | $245.58 | 2019 | |
| Neurocrine Biosciences, INC. | $215.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $124.75 | 2019 | |
| Tris Pharma INC | $102.02 | 2019 | |
| Avanir Pharmaceuticals, INC. | $97.78 | 2019 | |
| Abbvie INC. | $91.43 | 2021-2025 | |
| Neuronetics, INC. | $69.01 | 2019 | |
| Lundbeck LLC | $67.04 | 2019 | |
| Adlon Therapeutics L.P. | $61.20 | 2019 | |
| Ironshore Pharmaceuticals INC. | $60.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.17 | 2019 | |
| Neos Therapeutics, LP | $51.23 | 2019 | |
| Jazz Pharmaceuticals INC. | $36.04 | 2019 | |
| Allergan, INC. | $28.58 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $27.47 | 2019 | |
| Bausch Health US, LLC | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Humphrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.